Epinephrine Injection USP — Class II drug recall D-1260-2020
Terminated recall by Teva Pharmaceuticals USA, reported 2020-05-13. CGMP Deviations: Precautions taken due to Out-of-specification for trigger force for a non-marketed lot number
| Recall number | D-1260-2020 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Parsippany, NJ, United States |
| Recall initiated | 2020-03-05 |
| Classified | 2020-05-05 |
| Reported by FDA | 2020-05-13 |
| Terminated | 2020-11-19 |
| Reason classes | cgmp |
| NDC | 00093-5985, 00093-5985-19, 00093-5985-27, 00093-5986, 00093-5986-19, 00093-5986-27 |
| Lot numbers | 007F19AA |
| Expiration dates | 2021-04 |
Product
Epinephrine Injection USP, 0.3 mg (Auto-Injector), 0.3 mg/ 0.3 mL pre-filled syringe, Rx Only, Manufactured for Teva Pharmaceuticals USA, Inc. North Wales, PA 19454. NDC 0093-5986-27
Reason for recall
CGMP Deviations: Precautions taken due to Out-of-specification for trigger force for a non-marketed lot number that shares the same component.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1260-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.